$0.26 EPS Expected for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) This Quarter

Equities analysts expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) will report earnings of $0.26 per share for the current quarter, Zacks reports. Eleven analysts have made estimates for Neurocrine Biosciences’ earnings, with estimates ranging from ($0.02) to $0.51. Neurocrine Biosciences reported earnings of $0.33 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 21.2%. The firm is expected to report its next quarterly earnings report before the market opens on Monday, January 1st.

On average, analysts expect that Neurocrine Biosciences will report full year earnings of $1.81 per share for the current fiscal year, with EPS estimates ranging from $1.16 to $2.68. For the next fiscal year, analysts forecast that the business will post earnings of $3.38 per share, with EPS estimates ranging from $2.20 to $5.49. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last posted its quarterly earnings results on Friday, February 11th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by ($0.69). Neurocrine Biosciences had a net margin of 7.90% and a return on equity of 6.89%. The business had revenue of $312.00 million during the quarter, compared to analysts’ expectations of $317.72 million. During the same quarter in the previous year, the business posted $3.58 EPS. The company’s quarterly revenue was up 25.9% on a year-over-year basis.

Several research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $125.00 to $126.00 and gave the company an “overweight” rating in a report on Monday, April 4th. Barclays raised their price target on shares of Neurocrine Biosciences from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. StockNews.com upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, March 28th. Zacks Investment Research lowered shares of Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research note on Thursday. Finally, Piper Sandler lowered shares of Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $114.00 to $94.00 in a research note on Thursday, March 3rd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $111.17.

In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Monday, January 24th. The shares were sold at an average price of $74.43, for a total value of $1,116,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William H. Rastetter sold 10,728 shares of Neurocrine Biosciences stock in a transaction on Friday, April 1st. The stock was sold at an average price of $94.93, for a total transaction of $1,018,409.04. Following the completion of the transaction, the director now directly owns 34,022 shares of the company’s stock, valued at approximately $3,229,708.46. The disclosure for this sale can be found here. Insiders have sold 46,743 shares of company stock valued at $3,957,821 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in NBIX. Whittier Trust Co. boosted its holdings in shares of Neurocrine Biosciences by 102.8% during the fourth quarter. Whittier Trust Co. now owns 290 shares of the company’s stock valued at $25,000 after acquiring an additional 147 shares during the period. Moors & Cabot Inc. acquired a new position in shares of Neurocrine Biosciences during the third quarter valued at $30,000. KB Financial Partners LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $33,000. Orion Capital Management LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $34,000. Finally, CI Investments Inc. bought a new stake in shares of Neurocrine Biosciences during the third quarter valued at about $39,000. 95.93% of the stock is owned by institutional investors.

NASDAQ NBIX opened at $99.27 on Monday. Neurocrine Biosciences has a one year low of $71.88 and a one year high of $108.01. The company’s 50 day moving average price is $91.23 and its 200 day moving average price is $89.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.83 and a current ratio of 3.96. The firm has a market capitalization of $9.48 billion, a price-to-earnings ratio of 109.09, a PEG ratio of 4.74 and a beta of 0.71.

Neurocrine Biosciences Company Profile (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Stories

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.